Cargando…
Radiolabeled Nanoparticles for Multimodality Tumor Imaging
Each imaging modality has its own unique strengths. Multimodality imaging, taking advantages of strengths from two or more imaging modalities, can provide overall structural, functional, and molecular information, offering the prospect of improved diagnostic and therapeutic monitoring abilities. The...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915092/ https://www.ncbi.nlm.nih.gov/pubmed/24505237 http://dx.doi.org/10.7150/thno.7341 |
_version_ | 1782302522810040320 |
---|---|
author | Xing, Yan Zhao, Jinhua Conti, Peter S. Chen, Kai |
author_facet | Xing, Yan Zhao, Jinhua Conti, Peter S. Chen, Kai |
author_sort | Xing, Yan |
collection | PubMed |
description | Each imaging modality has its own unique strengths. Multimodality imaging, taking advantages of strengths from two or more imaging modalities, can provide overall structural, functional, and molecular information, offering the prospect of improved diagnostic and therapeutic monitoring abilities. The devices of molecular imaging with multimodality and multifunction are of great value for cancer diagnosis and treatment, and greatly accelerate the development of radionuclide-based multimodal molecular imaging. Radiolabeled nanoparticles bearing intrinsic properties have gained great interest in multimodality tumor imaging over the past decade. Significant breakthrough has been made toward the development of various radiolabeled nanoparticles, which can be used as novel cancer diagnostic tools in multimodality imaging systems. It is expected that quantitative multimodality imaging with multifunctional radiolabeled nanoparticles will afford accurate and precise assessment of biological signatures in cancer in a real-time manner and thus, pave the path towards personalized cancer medicine. This review addresses advantages and challenges in developing multimodality imaging probes by using different types of nanoparticles, and summarizes the recent advances in the applications of radiolabeled nanoparticles for multimodal imaging of tumor. The key issues involved in the translation of radiolabeled nanoparticles to the clinic are also discussed. |
format | Online Article Text |
id | pubmed-3915092 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-39150922014-02-06 Radiolabeled Nanoparticles for Multimodality Tumor Imaging Xing, Yan Zhao, Jinhua Conti, Peter S. Chen, Kai Theranostics Review Each imaging modality has its own unique strengths. Multimodality imaging, taking advantages of strengths from two or more imaging modalities, can provide overall structural, functional, and molecular information, offering the prospect of improved diagnostic and therapeutic monitoring abilities. The devices of molecular imaging with multimodality and multifunction are of great value for cancer diagnosis and treatment, and greatly accelerate the development of radionuclide-based multimodal molecular imaging. Radiolabeled nanoparticles bearing intrinsic properties have gained great interest in multimodality tumor imaging over the past decade. Significant breakthrough has been made toward the development of various radiolabeled nanoparticles, which can be used as novel cancer diagnostic tools in multimodality imaging systems. It is expected that quantitative multimodality imaging with multifunctional radiolabeled nanoparticles will afford accurate and precise assessment of biological signatures in cancer in a real-time manner and thus, pave the path towards personalized cancer medicine. This review addresses advantages and challenges in developing multimodality imaging probes by using different types of nanoparticles, and summarizes the recent advances in the applications of radiolabeled nanoparticles for multimodal imaging of tumor. The key issues involved in the translation of radiolabeled nanoparticles to the clinic are also discussed. Ivyspring International Publisher 2014-01-24 /pmc/articles/PMC3915092/ /pubmed/24505237 http://dx.doi.org/10.7150/thno.7341 Text en © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. |
spellingShingle | Review Xing, Yan Zhao, Jinhua Conti, Peter S. Chen, Kai Radiolabeled Nanoparticles for Multimodality Tumor Imaging |
title | Radiolabeled Nanoparticles for Multimodality Tumor Imaging |
title_full | Radiolabeled Nanoparticles for Multimodality Tumor Imaging |
title_fullStr | Radiolabeled Nanoparticles for Multimodality Tumor Imaging |
title_full_unstemmed | Radiolabeled Nanoparticles for Multimodality Tumor Imaging |
title_short | Radiolabeled Nanoparticles for Multimodality Tumor Imaging |
title_sort | radiolabeled nanoparticles for multimodality tumor imaging |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915092/ https://www.ncbi.nlm.nih.gov/pubmed/24505237 http://dx.doi.org/10.7150/thno.7341 |
work_keys_str_mv | AT xingyan radiolabelednanoparticlesformultimodalitytumorimaging AT zhaojinhua radiolabelednanoparticlesformultimodalitytumorimaging AT contipeters radiolabelednanoparticlesformultimodalitytumorimaging AT chenkai radiolabelednanoparticlesformultimodalitytumorimaging |